Biotech

All Articles

OS Therapies refiles $6M IPO to cash HER2 medication, preclinical ADCs

.OS Therapies are going to detail on the NYSE American supply swap this morning via a $6.4 thousand ...

ALX's waning CD47 feedback fee delivers stock spiraling down

.ALX Oncology's stage 2 gastric cancer action price has actually weakened. After viewing its own CD4...

Ionis centers eye ailment coming from targets of Roche-partnered possibility after data disappoint

.Another of Ionis Pharmaceuticals' crucial midphase readouts has fallen short of expectations, causi...

Biogen's chief executive officer pointed out no high-risk handle 2023. He's ready to become bold

.While Biogen's pharma peers are hunting for late-stage resources with little bit of danger, CEO Chr...

Instil refills pipeline in $2B biobucks handle ImmunOnco

.Instil Biography has actually been actually a biotech in search of a pipe after it ditched its lead...

Biogen leaves Denali Alzheimer's collab

.Biogen has actually handed back civil liberties to an early Alzheimer's ailment system to Denali Th...

Takeda faucets brand-new mind people oncology organization-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of substantial management hirings, shootings and...

Vertex, beaten through AATD once again, loses 2 assets on discard stack

.Vertex's effort to handle an unusual genetic disease has struck another obstacle. The biotech threw...

Vir gains 3 T-cell engagers from Sanofi, lays off 25% of team

.Vir Biotechnology's second-quarter profits file had not been except significant headlines. The comp...

Galapagos stops CAR-T cell treatment trial over Parkinsonism case

.Galapagos has actually stopped briefly registration in a trial of a BCMA-directed CAR-T tissue ther...